Catalent price target raised to $82 from $75 at Baird

Baird analyst Evan Stover raised the firm’s price target on Catalent (CTLT) to $82 from $75 and keeps an Outperform rating on the shares. The analyst said they provided a mixed bag update, though good vibes win out largely due to the Moderna (MRNA) extension and expansion beyond COVID.